ALFA Filings
Every announcement, straight from the exchange
Every Aurobindo Pharma regulatory approval announcement on NSE and BSE, newest first, each with its own page.
Time
5 announcements with these filters
Aurobindo Pharma received USFDA final approval for its first MDI product, Beclomethasone Dipropionate HFA Inhalation Aerosol. The US market for this segment is estimated at US$301 million.
Aurobindo Pharma's subsidiary, CuraTeQ Biologics, received ANVISA (Brazil) approval for its biosimilars manufacturing facility in Hyderabad. This approval enables supply to Brazilian and Latin American markets.
Aurobindo Pharma received final US FDA approval for Tofacitinib Tablets used in treating rheumatoid arthritis. The product will be manufactured by its subsidiary and launched immediately.
Aurobindo Pharma subsidiary CuraTeQ received CDSCO marketing approval for Bevqolva, a bevacizumab biosimilar. The authorisation permits domestic manufacturing and marketing for metastatic colorectal cancer treatment.
Aurobindo Pharma's subsidiary, CuraTeQ Biologics, received marketing authorization (NOC) from Health Canada for its Bevacizumab biosimilar, Bevqolva™. This regulatory approval follows earlier UK authorization and commercial launch. The biosimilar, used to treat colorectal and lung cancers, will be available in 100 mg and 400 mg formulations, strengthening Aurobindo's global biosimilar portfolio.